{
    "ticker": "PTGX",
    "name": "Protagonist Therapeutics, Inc.",
    "description": "Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune diseases and other serious conditions. Founded in 2015 and based in Newark, California, Protagonist is dedicated to advancing its proprietary peptide-based drug candidates through innovative science and a deep understanding of human biology. The company's lead product candidates include PTG-100 and PTG-200, designed to treat conditions such as ulcerative colitis and Crohn's disease. Protagonist employs a unique approach to drug development, leveraging its proprietary peptide technology platform to create oral peptide therapeutics that can be administered conveniently and effectively. The company is committed to addressing unmet medical needs in the field of immunology and gastroenterology, aiming to improve patient outcomes and quality of life. With a strong pipeline and substantial clinical data, Protagonist is poised to make significant contributions to the therapeutic landscape in autoimmune disorders.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Newark, California, USA",
    "founded": "2015",
    "website": "https://www.protagonist-inc.com",
    "ceo": "Dino Dina",
    "social_media": {
        "twitter": "https://twitter.com/protagonisttx",
        "linkedin": "https://www.linkedin.com/company/protagonist-therapeutics/"
    },
    "investor_relations": "https://investors.protagonist-inc.com",
    "key_executives": [
        {
            "name": "Dino Dina",
            "position": "CEO"
        },
        {
            "name": "Michael L. Lichtenstein",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PTG-100",
                "PTG-200"
            ]
        }
    ],
    "seo": {
        "meta_title": "Protagonist Therapeutics, Inc. | Innovative Biopharmaceuticals",
        "meta_description": "Explore Protagonist Therapeutics, Inc., a leader in peptide-based drug development for autoimmune diseases. Learn about our innovative therapies and commitment to patient care.",
        "keywords": [
            "Protagonist Therapeutics",
            "Biopharmaceuticals",
            "Autoimmune Diseases",
            "Peptide Therapeutics",
            "PTG-100",
            "PTG-200"
        ]
    },
    "faq": [
        {
            "question": "What is Protagonist Therapeutics known for?",
            "answer": "Protagonist Therapeutics is known for developing novel peptide-based therapies for autoimmune diseases."
        },
        {
            "question": "Who is the CEO of Protagonist Therapeutics?",
            "answer": "Dino Dina is the CEO of Protagonist Therapeutics, Inc."
        },
        {
            "question": "Where is Protagonist Therapeutics headquartered?",
            "answer": "Protagonist Therapeutics is headquartered in Newark, California, USA."
        },
        {
            "question": "What are Protagonist's main products?",
            "answer": "Protagonist's main products include PTG-100 and PTG-200, aimed at treating autoimmune conditions."
        },
        {
            "question": "When was Protagonist Therapeutics founded?",
            "answer": "Protagonist Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "AMGN",
        "ABBV",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRNA",
        "GILD"
    ]
}